Lipodystrophy, lipid profile changes, and low serum retinol and carotenoid levels in children and adolescents with acquired immunodeficiency syndrome

Nutrition

Volumn 26, Issue 6, 2010, Pages 612-616

  Beraldo Battistini, Tânia Regina ^a   Saccardo Sarni, Roseli Oselka ^a,b   Suano de Souza, Fabíola Isabel ^a,b   Pitta, Tassiana Sacchi ^a   Fernandes, Ana Paula ^a   Hix, Sonia ^a   Affonso Fonseca, Fernando Luiz ^a   Tardini, Priscila Chemiotti ^a   Pinho dos Santos, Valter ^a   Lopez, Fábio Ancona ^b  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Carotene; Antiretroviral therapy; Children; Human immunodeficiency virus; Retinol; Vitamin A

Indexed keywords

BETA CAROTENE; CAROTENOID; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RETINOL; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTIRETROVIRUS AGENT; GLUCOSE BLOOD LEVEL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ARTICLE; CHILD; CHILD NUTRITION; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INSULIN RESISTANCE; LIPID METABOLISM; LIPID PEROXIDATION; LIPODYSTROPHY; MALE; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; RETINOL DEFICIENCY; VITAMIN BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; DEFICIENCY; DYSLIPIDEMIAS; GLUCOSE BLOOD LEVEL; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; METABOLISM; OXIDATIVE STRESS; PRESCHOOL CHILD; PREVALENCE; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ANTI-RETROVIRAL AGENTS; BETA CAROTENE; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HIV; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PREVALENCE; VITAMIN A; VITAMIN A DEFICIENCY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77952744104     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2009.06.024     Document Type: Article

References (44)

1. Velasco-Benitez C.A. Digestive, hepatic and nutritional manifestations in Latin-American children with HIV/AIDS. J Pediatr Gastroenterol Nutr 2008, 47:S24-S26.
2. Jaquet D., Lèvine M., Ortega-Rodriguez E., Faye A., Polak M., Vilmer E., et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000, 14:2123-2128.
3. Noor M.A., Seneviratne T., Aweeka F.T., Lo J.C., Schwarz J.M., Mulligan K., et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized placebo controlled study. AIDS 2000, 16:1-8.
4. Barbaro G., Fisher S.D., Lipshultz S.E. Pathogenesis of HIV associated cardiovascular complications. J Infect Dis 2001, 1:115-124.
5. Pinti M., Salomoni P., Cossarizza A. Anti-HIV drugs and the mitochondria. Biophys Biochem Acta 2006, 1757:700-707.
6. Tang A.M., Lanzilotti J., Hendricks K., Gerrior J., Ghosh M., Woods M., et al. Micronutrient: current issues for HIV care providers. AIDS 2005, 19:847-861.
7. Neves F.F., Vanucchi H., Jordão Junior A.A., Figueiredo J.F. Recommended dose for repair of serum vitamin A levels in patients with infection/AIDS may be insufficient because of high urinary losses. Nutrition 2006, 22:483-489.
8. Temesgen Z., Warnke D., Kasten M.J. Current status of antiretroviral therapy. Expert Opin Pharmacother 2006, 7:1541-1554.
9. Semba R.D., Graham N.M., Caiaffa W.T., Margolick J.B., Clement L., Vlahov D. Increased mortality associated with vitamin A deficiency during human immunodeficiency virus type 1 infection. Arch Intern Med 1993, 153:2149-2154.
10. Fawzi W.W., Mbise R.L., Hertzmark E., Fataki M.R., Herrera M.G., Ndossi G., et al. A randomized trial of vitamin A supplements in relation to mortality among human immunodeficiency virus-infected and uninfected children in Tanzania. Pediatr Infect Dis J 1999, 18:127-133.
11. Semba R., Ndugwa C., Perry R.T., Clark T.D., Jackson J.B., Melikian G., et al. Effect of periodic vitamin A supplementation on mortality and morbidity of human immunodeficiency virus-infected children in Uganda: a controlled clinical trial. Nutrition 2005, 21:25-31.
12. Fawzi W.W., Msamanga G.I., Spiegelman D., Wei R., Kapiga S., Villamor E., et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004, 351:23-32.
13. Semba R., Lyles C., Margolick J. Vitamin A supplementation and human immunodeficiency virus load in injection drug users. J Infect Dis 1998, 177:611-616.
14. Oh J., Hegele R.A. HIV-associated dyslipidemia: pathogenesis and treatment. Lancet Infect Dis 2007, 7:787-796.
15. Currier J.S., Lundgren J.D., Carr A., Klein D., Sabin C.A., Sax P.E., et al. Working Group 2. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly antiretroviral therapy. Circulation 2008, 118:e29-e35.
16. Grinspoon S. Diabetes mellitus, cardiovascular risk, and HIV disease. Circulation 2009, 119:770-772.
17. Centers for Disease Control and Prevention Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR 1998, 47:1-31.
18. Centers for Disease Control and Prevention Revised classification system for human immunodeficiency virus infection less than 13 years age. MMWR 1994, 43:1-10.
19. Associação Brasileira de Empresas de Pesquisa-2003. Available at: http://abep.org/codigosguia/ABEP_CCEB.pdf.
20. Monteiro C.A., Nazario C.L. Evolução de condicionantes ambientais da saúde na infância na cidade de São Paulo (1984-1996). Rev Saude Publica 2000, 34:13-18.
21. World Health Organization Physical status. The use and interpretation of anthropometry. WHO technical report series 854 1995, World Health Oganization, Geneva, p. 452.
22. Kuczmarski R.J., Ogden C.L. Grummer-Strawn. CDC growth charts: United States. Advance data from vital and health statistics, no 2000, National Center for Health Statistics, Hyattsville, MD, 314.
23. Marshall E.A., Tanner J.M. Growth and physiological development during adolescence. Annu Rev Med 1975, 19:283-300.
24. Valente A.M.M., Reis A.F., Machado D.M., Succi R.C.M., Chacra R. Alterações metabólicas da síndrome lipodistrófica do HIV. Arq Bras Endocrinol Metab 2005, 49:871-881.
25. Nierenberg D.W., Lester D.C. Determination of vitamins A and E in serum using a simplified clarification method and high-performance liquid chromatography. J Chromatogr 1985, 345:275-284.
26. Ford E.S., Gillespie C., Ballew C., Sowell A., Mannino D.M. Serum carotenoid concentrations in US children and adolescents. Am J Clin Nutr 2002, 76:818-827.
27. National Cholesterol Education Program (NCEP) Highlights of the report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992, 89:495-501.
28. Ohkawa H., Oshishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95:351-358.
29. Tresaco B., Bueno G., Pineda I., Moreno L.A., Garagorri J.M., Bueno M. Homeostatic model assessment (HOMA-IR) index cut-off values to identify the metabolic syndrome in children. J Physiol Biochem 2005, 61:381-388.
30. Dean A.G. Epi Info™ and Epi Map: current status and plans for Epi Info™ 2000. J Public Health Manag Pract 1999, 5:54-57.
31. SPSS base 13.0: base users guide 2004, SPSS, Chicago.
32. Amaya R.A., Kozinetz C.A., McMeans A., Schwarzwald H., Kline M.W. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002, 21:405-410.
33. Santos F.S., Rangel L.G.G., Saucedo G.P., Rosales G.V., Novales M.G.M. Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1 infected children treated with protease inhibitors. Arch Med Res 2006, 37:129-132.
34. Carr A., Samaras K., Thorisdottir A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
35. Verwell G., Saavedra-Lozano J., Van Rossum A.M.C., Ramilo O., de Groot R. Initiating highly antiretroviral therapy in human immunodeficiency virus type 1 in Europe and the Unites States. Pediatr Infect Dis J 2006, 25:987-994.
36. Shenkin A. Micronutrients in health and disease. Postgrad Med J 2006, 82:559-567.
37. European Pediatric Lipodystrophic Group Antiretroviral therapy, fat redistribution, and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004, 18:1443-1451.
38. Alves C., Oliveira A.C., Brites C. Lypodystrophic syndrome in children and adolescents with the immunodeficiency virus. Braz J Infect Dis 2008, 12:342-348.
39. Friis-Moller N., Reiss P., Sabin C.A., Weber R., Monforte A., El-Sadr W., et al. Class of antiretroviral drugs and the risk of myocardial infarction. DAD Study Group. N Engl J Med 2007, 356:1723-1735.
40. Drain P.K., Kupka R., Mugusi F., Fawzi W.W. Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy. Am J Clin Nutr 2007, 85:333-345.
41. Jared M.B., Barbra A.R., Daniel D.B. Use of serum retinol-binding protein for prediction of vitamin A deficiency. Am J Clin Nutr 2004, 79:218-225.
42. Schindler K., Haider D., Wolzt M., Rieger B., Gmeinhart A., Luger P., et al. Impact of antiretroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects. Eur J Clin Invest 2006, 36:640-646.
43. Srinivas A., Dias B.F. Antioxidants in HIV positive children. Indian J Pediatr 2008, 75:347-350.
44. Meagher E.A., Fitzgerald G.A. Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med 2000, 28:1745-1750.